NCT06477614

Anti-cancer DC Cell Vaccination to Treat Solid Tumors

Anti-cancer DC Cell Vaccination to Treat Advanced Solid Tumors: Phase I Clinical Trial

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.

Detailed description

1. Choose appropriate patients with advanced solid cancers, with written consent for this study; 2. Perform biopsy to get fresh sample for generation gp96 protein; Collect DC cells from the cancer patient; 3. Produce appropriate DC cell vaccine and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required; 4. To enhance the killing capability, cotreatment the patients with vaccine aduvants or PD1/PDL1/CTLA4 antibodies may be applied; 5. Evaluate the clinical results as needed.

Conditions

• Solid Tumor, Adult
• DC

Interventions

Type	Name	Description
BIOLOGICAL	DC cell Vaccine	Deliver DC cell vaccine into patients for anti-ancer therapy.

Timeline

• Start date: 2024-06-05
• Primary completion: 2030-12-30
• Completion: 2035-12-30
• First posted: 2024-06-27
• Last updated: 2024-06-27

Locations

1 site across 1 country: China